Skip to main content
VALN
NASDAQ Life Sciences

Major Institutional Investors Reduce Valneva Stake After Not Participating in €84M Offering

Analysis by Arik Shkolnikov
Sentiment info
Negative
Importance info
7
Price
$6
Mkt Cap
$611.821M
52W Low
$5.06
52W High
$12.25
Market data snapshot near publication time

summarizeSummary

Major institutional investors Bpifrance and Caisse des Depots updated their Schedule 13D, reporting a diluted stake after not participating in Valneva's recent €84 million offering and detailing net share sales totaling approximately $2.14 million.


check_boxKey Events

  • Dilution from Reserved Offering

    The reporting persons (Bpifrance and Caisse des Depots) did not participate in Valneva's recent €84 million reserved offering, which resulted in a dilution of their ownership percentages.

  • Bpifrance Participations Sells Shares

    Bpifrance Participations S.A. sold 356,003 ordinary shares for approximately €1.76 million in open market transactions during March 2026.

  • CDC Croissance Net Sales

    CDC Croissance S.A. acquired 130,000 ordinary shares for approximately €0.59 million and sold 289,645 ordinary shares for approximately €0.81 million in March 2026, resulting in net sales of approximately €0.22 million.

  • Updated Ownership Stake

    As of May 5, 2026, Bpifrance Participations holds 7.0% of voting rights, and Caisse des Depots et consignations holds 9.3% of voting rights, reflecting the impact of the offering and recent transactions.


auto_awesomeAnalysis

This Schedule 13D/A updates the holdings of major institutional investors, Bpifrance and Caisse des Depots, following Valneva's recent €84 million reserved offering. These investors chose not to participate in the offering, resulting in a dilution of their ownership percentages. Additionally, the filing details recent open market transactions, including Bpifrance Participations selling approximately €1.76 million worth of shares and CDC Croissance making net sales of approximately €0.22 million. This indicates a reduction in their overall stake, both actively through sales and passively through non-participation in the capital raise.

At the time of this filing, VALN was trading at $6.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $611.8M. The 52-week trading range was $5.06 to $12.25. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed VALN - Latest Insights

VALN
May 12, 2026, 5:09 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
VALN
Apr 30, 2026, 5:11 PM EDT
Filing Type: 6-K
Importance Score:
8
VALN
Apr 30, 2026, 1:15 AM EDT
Source: GlobeNewswire
Importance Score:
8
VALN
Mar 23, 2026, 4:06 PM EDT
Filing Type: 6-K
Importance Score:
8
VALN
Mar 18, 2026, 11:21 AM EDT
Filing Type: 6-K
Importance Score:
8
VALN
Mar 17, 2026, 4:33 PM EDT
Filing Type: 20-F
Importance Score:
9
VALN
Feb 19, 2026, 6:19 AM EST
Filing Type: 6-K
Importance Score:
8
VALN
Feb 13, 2026, 11:51 AM EST
Filing Type: 6-K
Importance Score:
8
VALN
Feb 03, 2026, 9:17 AM EST
Filing Type: 6-K
Importance Score:
7
VALN
Jan 20, 2026, 9:50 AM EST
Filing Type: 6-K
Importance Score:
9